Item 7.01 Regulation FD Disclosure.
On August 4, 2022, Alaunos Therapeutics, Inc. (the “Company”) issued a press
release announcing that Abhishek Srivastava, Ph.D., has joined the Company as
its Vice President of Technical Operations. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 7.01, including Exhibit 99.1, is being
“furnished” and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liability of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended (the “Securities Act”). The information
contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated
by reference into any registration statement or other document pursuant to the
Securities Act or into any filing or other document pursuant to the Exchange
Act, except as otherwise expressly stated in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 4, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses